Positions

Selected Publications

Academic Article

Year Title Altmetric
2021 Clinical characteristics, time course, treatment and outcomes of patients with immune checkpoint inhibitor-associated myocarditis.  Journal for ImmunoTherapy of Cancer.  9. 2021
2021 Multi-Site 11-Year Experience of Less-Intensive versus Intensive Therapies in Acute Myeloid Leukemia..  Blood.  2021
2021 Acute Myeloid Leukemia, Version 2.2021 Featured Updates to the NCCN Guidelines 2021
2021 Venetoclax with chemotherapy in relapse/refractory early T-cell precursor acute lymphoblastic leukemia 2021
2020 Myeloid/lymphoid neoplasms with eosinophilia and TK fusion genes, version 3.2021 2020
2020 Outcomes of high-risk acute promyelocytic leukemia patients treated with arsenic trioxide (ATO)/all trans retinoic acid (ATRA) based induction and consolidation without maintenance phase: A case Series.  Hematology/Oncology and Stem Cell Therapy.  13:143-146. 2020
2020 Collaborative cardiovascular management of patients with chronic myeloid leukemia on tyrosine kinase inhibitors 2020
2020 Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study.  Journal for ImmunoTherapy of Cancer.  8. 2020
2020 Observation Versus Immediate Reinduction for Acute Myeloid Leukemia Patients With Indeterminate Day 14 Bone Marrow Results.  Clinical Lymphoma, Myeloma and Leukemia.  20:31-38. 2020
2019 Acute promyelocytic leukemia during pregnancy: A case report and 10-year institutional review of hematologic malignancies during pregnancy 2019
2019 Genetic Alterations at Diagnosis Predict Outcome of AML Patients Age 60 or Older Undergoing Allogeneic Transplantation in First Remission.  Blood.  134:48. 2019
2019 Radiological imaging and bone marrow biopsy in staging of cutaneous B-cell lymphoma.  British Journal of Haematology.  184:674-676. 2019
2019 Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: Case Series and Review of the Literature.  Case Reports in Oncology.  12:260-276. 2019
2018 Intensive chemotherapy vs. hypomethylating agents in older adults with newly diagnosed high-risk acute myeloid leukemia: A single center experience.  Leukemia Research.  75:29-35. 2018
2018 All-trans-retinoic-acid and arsenic trioxide induced remission in promyelocytic blast crisis.  Leukemia Research Reports.  10:16-19. 2018
2017 Treatment of Relapsed/Refractory Acute Myeloid Leukemia.  Current Treatment Options in Oncology.  18. 2017
2017 Dexrazoxane for cardioprotection in older adults with acute myeloid leukemia.  Leukemia Research Reports.  7:36-39. 2017
2017 Remission of Severe, Relapsed, and Refractory TTP after Multiple Cycles of Bortezomib..  Case Reports in Hematology.  2017:9681832. 2017
2016 VEGF inhibitors in renal cell carcinoma 2016
2016 Spotlight on pembrolizumab in non-small cell lung cancer: The evidence to date.  OncoTargets and Therapy.  9:5855-5866. 2016
2016 Spontaneous Remission in an Older Patient with Relapsed FLT3 ITD Mutant AML..  Case Reports in Hematology.  2016:1259759. 2016
2014 Remission of rheumatoid arthritis on brentuximab vedotin.  Rheumatology.  53:2314-2315. 2014
2014 Rational combination of dual PI3K/mTOR blockade and Bcl-2/-xL inhibition in AML.  Physiological Genomics.  46:448-456. 2014
2014 Isolated gastric myeloid sarcoma: a case report and review of the literature..  Case Reports in Hematology.  2014:541807. 2014
2011 Obesity and low vision as a result of excessive Internet use and television viewing.  International Journal of Food Sciences and Nutrition.  62:60-62. 2011
2010 Do excessive internet use, television viewing and poor lifestyle habits affect low vision in school children?.  Journal of Child Health Care.  14:375-385. 2010

Chapter

Year Title Altmetric
2014 Can we cure CML without transplantation?.  279-326. 2014

Research Overview

  • Dr Vachhani’s primary interest is in hematological malignancies, particularly acute myeloid leukemia (AML) and myeloproliferative neoplasms (MPN). His specific research interests include developmental therapeutics and clinical trials for high-risk, elderly and relapsed AML.

    • Principal Investigator On

  • Private Grant  awarded by AMGEN, INC.^ 2020 - 2024
  • UAB 19113: A Phase 1 Study of NTX-301, an Oral DNMT1 Inhibitor, in Patients with MDS and AML  awarded by SOUTHERN RESEARCH INSTITUTE 2020 - 2024
  • Private Grant  awarded by INCYTE CORPORATION 2020 - 2024
  • Private Grant  awarded by AMGEN, INC.^ 2019 - 2024
  • Private Grant  awarded by CHIMERIX, INC. 2021 - 2024
  • Private Grant  awarded by KARTOS THERAPEUTICS INC. 2019 - 2024
  • Private Grant  awarded by KARTOS THERAPEUTICS INC. 2019 - 2024
  • Private Grant  awarded by KARTOS THERAPEUTICS INC. 2021 - 2024
  • Private Grant  awarded by TAKEDA DEVELOPMENT CENTER AMERICAS, INC. 2021 - 2024
  • Private Grant  awarded by BLUEPRINT MEDICINES CORPORATION 2021 - 2024
  • Private Grant  awarded by ASTEX PHARMACEUTICALS 2021 - 2024
  • Private Grant  awarded by ABBVIE INC 2021 - 2024
  • Private Grant  awarded by FORTY SEVEN, INC. 2020 - 2023
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2020 - 2023
  • Private Grant  awarded by ABBVIE INC 2019 - 2023
  • Private Grant  awarded by ZENO MANAGEMENT 2021 - 2022
  • Private Grant  awarded by CTI BIOPHARMA CORP 2020 - 2022
  • Private Grant  awarded by AVEO PHARMACEUTICALS, INC 2020 - 2022
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2021 - 2022
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2020 - 2021
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2020 - 2021
  • Private Grant  awarded by MARKER THERAPEUTICS INC 2021

    • Investigator On

  • UAB 2078: A Multi-Center, Open-Label, Phase 1/2 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-101 Monotherapy and AB-101 Plus Rituximab in Patients with Relapsed/Refractory Non–Hodgkin Lymphoma of B-Cell Origin  awarded by ARTIVA BIOTHERAPEUTICS INC 2021 - 2026
  • UAB 1923: A Phase 2 Front-Line PET/CT-2 Response-Adapted Brentuximab Vedotin and Nivolumab Incorporated and Radiation-Free Management of Early Stage Classical Hodgkin Lymphoma (cHL) study  awarded by City of Hope 2021 - 2026
  • SWOG Purchase Services Agreement  awarded by Oregon Health & Science University 2020 - 2025
  • Private Grant  awarded by JUNO THERAPEUTICS 2019 - 2024
  • Private Grant  awarded by TG THERAPEUTICS 2020 - 2024
  • Private Grant  awarded by TG THERAPEUTICS 2019 - 2024
  • Private Grant  awarded by MILLENNIUM PHARMACEUTICALS, INC. 2019 - 2024
  • Private Grant  awarded by DELTA-FLY PHARMA INC 2021 - 2024
  • Private Grant  awarded by SUTRO BIOPHARM 2020 - 2024
  • Private Grant  awarded by KITE PHARMA 2019 - 2024
  • Private Grant  awarded by ABBVIE INC 2021 - 2024
  • Private Grant  awarded by ASCENTAGE PHARMA GROUP INC 2021 - 2024
  • Private Grant  awarded by ASTEX PHARMACEUTICALS 2019 - 2024
  • ECOG-ACRIN Purchase Service Agreement  awarded by Eastern Cooperative Oncology Group 2019 - 2024
  • Private Grant  awarded by ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC. - NEW 2021 - 2024
  • Private Grant  awarded by MARKER THERAPEUTICS INC 2021 - 2024
  • Private Grant  awarded by SELLAS LIFE SCIENCES GROUP, INC. 2020 - 2023
  • Private Grant  awarded by GlaxoSmithKline 2020 - 2023
  • Reduced Intensity Conditioning for Haploidentical Bone Marrow Transplantation in Patients with Symptomatic Sickle Cell Disease, BMT CTN PROTOCOL #1507  awarded by National Marrow Donor Program 2017 - 2023
  • Private Grant  awarded by JUNO THERAPEUTICS 2020 - 2023
  • Private Grant  awarded by ASTEX PHARMACEUTICALS 2018 - 2023
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2020 - 2023
  • Private Grant  awarded by INCYTE CORPORATION 2017 - 2022
  • Private Grant  awarded by AFFIMED GMBH 2020 - 2022
  • Private Grant  awarded by FORTY SEVEN, INC. 2018 - 2022
  • Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS 2019 - 2022
  • Comprehensive Cancer Center Core Support Grant - Create Access to Targeted Cancer Therapy for Underserved Populations (CATCH-UP)  awarded by National Cancer Institute/NIH/DHHS 2019 - 2022
  • Private Grant  awarded by INNATE PHARMA 2020 - 2022
  • Private Grant  awarded by INCYTE CORPORATION 2016 - 2021
  • Private Grant  awarded by RHIZEN PHARMACEUTICALS SA 2018 - 2020
  • Private Grant  awarded by GlaxoSmithKline 2019 - 2020
  • ECOG-ACRIN Purchase Service Agreement  awarded by Eastern Cooperative Oncology Group 2014 - 2020
  • Southwest Oncology Group Purchase Service Agreement  awarded by Oregon Health & Science University 2015 - 2020
  • Private Grant  awarded by IMMUNOGEN, INC. 2018 - 2019
  • Private Grant  awarded by ONO PHARMACEUTICAL COMPANY LTD 2019
  • Private Grant  awarded by IMMUNOGEN, INC. 2018 - 2019
  • Private Grant  awarded by AMGEN, INC.^ 2018 - 2019
  • Private Grant  awarded by TRACON PHARMACEUTICALS, INC. 2017

    • Education And Training

  • Doctor of Medicine, 2012

    • Full Name

  • Pankit Vachhani